HX 1920

Drug Profile

HX 1920

Latest Information Update: 31 May 1995

Price : $50

At a glance

  • Originator Asahi Kasei
  • Class Anti-inflammatories; Antiallergics; Antineoplastics; Radioprotectives
  • Mechanism of Action Hyaluronidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Radiation injuries

Most Recent Events

  • 23 May 1995 Discontinued-Preclinical for Radiation injuries (Prevention)/Radioprotection in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top